Novartis Woos Payers With Data Showing Entresto Earns Its Keep
Executive Summary
With Entresto sales slowly climbing to $53m in third quarter, Novartis releases data supporting value of heart failure drug in preventing costly hospitalizations at the annual American Heart Association meeting.
You may also be interested in...
CAR-T Commercialization Strategies: Views From Novartis And Kite
At recent industry events, Novartis and Kite Pharma highlighted opportunities and addressed challenges they face as they prepare to commercialize their CAR-T therapies. A report from Datamonitor Healthcare.
Enbrel's First Outcomes Contract Is With Harvard Pilgrim; Others May Follow
Amgen seeking additional outcomes-based contracts in rheumatoid arthritis through collaboration with Inovalon/Avalere.
J&J Outlines Pricing Transparency Plan, Will Others Follow?
CEO Gorsky describes J&J’s approach to drug pricing and pledges to provide more detail in an annual transparency report. Investor pressure regarding the pricing debate continued during the Novartis earnings call. Value arguments expected to dominate pharma’s message.